FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group

Transplantation Proceedings
R Mendez

Abstract

The effective dose of MMF with FK 506 has not been previously studied in a prospective, randomized, controlled setting. In the present study, we evaluated two different daily doses of MMF (1 and 2 g) and compared it to the historically conventional therapy of AZA. At 6 months post-transplant, we found no significant difference in the incidence of acute rejection between the AZA group and the MMF 1 g group. However, patients who started on MMF 2 g/d had significantly delayed and lower incidence of acute rejection as compared to the other two groups. We found that patients who were initiated on MMF 2 g frequently had their dose lowered, primarily for gastrointestinal or hematologic symptoms; by 6 months after-transplant, patients in the MMF 2 g group had a mean dose of 1.5 g. It is unclear from this study if initiating patients on MMF 1.5 g in combination with FK 506 would be as effective as initiating a patient on MMF 2 g. Further studies of the combination of FK 506 and MMF in kidney transplant recipients to further define the optimal dosing regimen are warranted. In summary, the combination of FK 506 and MMF is well-tolerated, safe, and effective in cadaveric kidney transplant recipients.

Citations

Sep 9, 1999·Liver Transplantation and Surgery : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·J I HerreroJ Prieto
Feb 10, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Francesca Mencarelli, Stephen D Marks
Feb 26, 2005·Journal of Cardiac Failure·Osama El-SayedCarl V Leier
Apr 8, 2009·European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery·Stephan KoromWalter Weder
Sep 7, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Michel HaddadWilliam J Kostuk
May 18, 2005·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Howard J EisenUNKNOWN Mycophenolate Mofetil Cardiac Study Investigators
Mar 26, 2004·Transplantation Proceedings·J O O'NeillR C Starling
Mar 26, 2004·Transplantation Proceedings·M Hummel, R Hetzer
Mar 26, 2004·Transplantation Proceedings·N R Banner, M H Yacoub
Mar 26, 2004·Transplantation Proceedings·J K Patel, J A Kobashigawa
Jul 24, 2001·The Annals of Thoracic Surgery·T E OaksN D Kon
Nov 6, 2001·Clinica Chimica Acta; International Journal of Clinical Chemistry·H G SchneiderT Kotsimbos
Mar 19, 1999·Disease-a-month : DM·E WinkelM R Costanzo
Jan 5, 2000·Transplantation Proceedings·J P van Hooff, M H Christiaans
Nov 27, 1999·Transplantation Proceedings·J P van HooffM H Christiaans
Nov 27, 1999·Transplantation Proceedings·J P SquiffletY Vanrenterghem
Apr 13, 1999·Lancet·M D DentonM H Sayegh
Jul 6, 2000·Immunopharmacology·T S Mele, P F Halloran
Oct 6, 2000·Journal of Hepatology·A Dhawan, G Mieli-Vergani
Aug 16, 2002·Transplant Immunology·Henk-Jan SchuurmanChristos Papageorgiou
Apr 20, 2001·Critical Reviews in Oncology/hematology·N BasaraA A Fauser
Oct 12, 2001·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·A I DipchandM M Boucek
Jun 12, 2002·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Clifford ChinDaniel Bernstein
Sep 17, 2002·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Takeo TedoriyaPeter S Macdonald
Jan 22, 2004·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·Klaus PethigAxel Haverich
Dec 28, 1999·The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation·M CarrierL C Pelletier
Jun 17, 2000·Progress in Pediatric Cardiology·B A Pietra, M M Boucek
Jan 7, 2005·Seminars in Thoracic and Cardiovascular Surgery·Katherine Lietz, Leslie W Miller
Jan 7, 2005·Seminars in Thoracic and Cardiovascular Surgery·Jignesh K Patel, Jon A Kobashigawa
May 28, 2004·Journal of Virology·Laura L Hermann, Kevin M Coombs
Jan 18, 2002·Heart·Mario C Deng
Apr 6, 2011·Circulation·Vincent LiuMark A Hlatky
Nov 5, 2002·Journal of Clinical Pharmacology·Ryuji KatoKazuyuki Ueno
Aug 21, 2009·Clinical Pharmacokinetics·Caroline Monchaud, Pierre Marquet
Jul 20, 2011·Indian Journal of Nephrology·S ParameswaranV Sakhuja
Mar 16, 2001·Expert Opinion on Pharmacotherapy·G CiancioJ Miller
Jan 12, 2007·The Journal of Trauma·Homer C TienFrederick D Brenneman
Dec 4, 2015·The Cochrane Database of Systematic Reviews·Martin WagnerKatrin Uhlig

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.